KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study. PMID 39002179 · ESMO Open · 2024-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial. PMID 38996519 · ESMO Open · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial. PMID 38963459 · Clin Pharmacokinet · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. PMID 38936379 · Lancet Oncol · 2024-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PMID 38925294 · Diabetes Res Clin Pract · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. PMID 38898120 · Nat Med · 2024-Jul This is an original, formal report of a phase 2/3 trial in oncology (NSCLC) with a drug intervention, but it is single-arm (not randomized) and its primary efficacy endpoint is objective response rate (ORR), not a time-to-event efficacy endpoint as required for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. PMID 38888681 · Am J Clin Dermatol · 2024-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial. PMID 38862742 · Br J Cancer · 2024-Jul The record describes a secondary analysis of a randomized Phase III trial (SSG XVIII/AIO) evaluating adjuvant imatinib in high-risk GIST, with a focus on the subset of patients with rupture. It reports recurrence-free survival and overall survival (time-to-event endpoints) and includes a drug intervention. The publication is classified as a 'secondary' report type because it is a pre-specified or post-hoc analysis of the primary trial, but it is an original result report with formal efficacy endpoints, not a post-hoc subgroup, biomarker-only, quality-of-life, safety-only, or health-economic analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. PMID 38861871 · EBioMedicine · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of early nutritional intervention on oral mucositis and basic conditions in patients receiving radiotherapy for head and neck cancer: Randomized controlled trial (ChiCTR2000031418). PMID 38833872 · Clin Nutr · 2024-Jul The trial is randomized, oncologic, and human, with reported OS and PFS endpoints. However, the intervention is non-drug (nutritional support), and the primary endpoint is a non-time-to-event outcome (oral mucositis incidence). The phase is not explicitly established as Phase III/IIIb or Phase II/III. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study. PMID 38830959 · Leukemia · 2024-Jul The record meets oncology, human, phase III, time-to-event, and drug intervention criteria, but it fails to explicitly establish randomization, which is a required criterion for eligibility. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study). PMID 38830303 · Lung Cancer · 2024-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. PMID 38824269 · Target Oncol · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial. PMID 38820889 · Oral Oncol · 2024-Jul The report describes a secondary analysis of a randomized phase II/III oncology trial. While it meets criteria for being an oncology, human, randomized, phase III, drug-intervention, and original-result report, it fails the key time-to-event efficacy endpoint criterion. The primary outcome is acute kidney injury (a safety/toxicity endpoint), not an efficacy endpoint like OS or PFS.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. PMID 38810600 · Pediatr Neurol · 2024-Jul 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparing prospectively assigned trial and real-world lung cancer patients. PMID 38785683 · J Comp Eff Res · 2024-Jul The record is an observational comparative study evaluating the comparability of a 'probable clinical trial' cohort and a real-world cohort, not a report from a randomized trial. It lacks a specified drug intervention and does not present original results from a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. PMID 38778549 · United European Gastroenterol J · 2024-Jul Eligibility criteria require oncology focus and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.). This report is a safety analysis for ulcerative colitis, a non-oncology condition, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optical enhancement mode 2 improves the detection rate of gastric neoplastic lesion in high-risk populations: A multicenter randomized controlled clinical study. PMID 38753528 · United European Gastroenterol J · 2024-Jul The record does not meet the core eligibility criteria for a drug-containing Phase II/III or III/IIIb randomized trial with a time-to-event efficacy endpoint. While it is a randomized oncology trial with original results, it evaluates a diagnostic imaging technique, not a drug intervention, and its primary endpoint is not a time-to-event measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis. PMID 38740091 · Radiother Oncol · 2024-Jul The record describes a randomized trial with a drug intervention (nintedanib) for radiation pneumonitis in lung cancer patients, but the phase is not explicitly stated as Phase III or definitive. The primary outcome is biomarker analysis of serum proteins correlated with pulmonary exacerbations, which is not a time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for a primary/key secondary time-to-event outcome in a Phase III/IIIb or definitive trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. PMID 38729054 · Eur J Cancer · 2024-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial. PMID 38723593 · J Urol · 2024-Jul 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. PMID 38716823 · Aliment Pharmacol Ther · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial. PMID 38706726 · Clin Transl Radiat Oncol · 2024-Jul The study is a randomized phase 3 trial for a human malignancy, but it does not include a drug intervention (radiation therapy only) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is erectile function preservation, which is a quality-of-life or safety endpoint, not a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. PMID 38704840 · J Urol · 2024-Jul Eligible on all criteria except randomization; the study is an open-label Phase 3 trial without a randomized control arm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. PMID 38704093 · Ann Oncol · 2024-Jul The record is a pre-planned translational analysis of a randomized trial (MITO END-3) in advanced endometrial cancer, reporting PFS by molecular subgroups. While it meets criteria for oncology, human, randomized, drug intervention, time-to-event endpoint, and original result, the phase of the parent trial is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, the report type is a pre-planned translational/biomarker subgroup analysis, not the primary efficacy report of the randomized trial. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. PMID 38698175 · Am J Clin Dermatol · 2024-Jul The study is a randomized, Phase 3 trial with a drug intervention and original results, but it is not an oncology study and does not report a primary time-to-event efficacy endpoint relevant to malignant neoplasms.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ESHO 1-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology. PMID 38670266 · Radiother Oncol · 2024-Jul 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Image guided radiotherapy in curative treatment for prostate cancer. 5-year results from a randomized controlled trial (RIC-trial). PMID 38670265 · Radiother Oncol · 2024-Jul The record is a randomized, oncology, human trial with a time-to-event endpoint (PFS). However, it does not include a drug-containing intervention (radiotherapy technique comparison with hormonal therapy background), and the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial. PMID 38649618 · Breast Cancer Res Treat · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Feasibility of intraoperative pathologic examination for sentinel lymph nodes during sentinel node navigation surgery in early gastric cancer: results of pathologic protocol for SENORITA trial. PMID 38647977 · Gastric Cancer · 2024-Jul The report is an oncology, human, randomized trial with an original result, but it is not eligible because it is not a Phase III/IIIb or Phase II/III trial, lacks a drug-containing intervention, and does not report a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled. PMID 38627159 · Semin Nucl Med · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. PMID 38622840 · Am J Hematol · 2024-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial. PMID 38616209 · Ann Surg Oncol · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. PMID 38614387 · J Thromb Haemost · 2024-Jul The study is a Phase 3 trial of a drug-containing intervention (gene therapy) in humans with original results. However, it is not an oncology study (hemophilia A) and lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.); the primary efficacy endpoint is annualized bleeding rate, a count outcome, not a time-to-event measure.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. PMID 38587643 · Eur J Nucl Med Mol Imaging · 2024-Jul The record is a secondary, biomarker-focused substudy analyzing predictors of PET detection. It does not report primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, etc.) or associated Kaplan-Meier/HR results, which are required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). PMID 38583574 · Ann Oncol · 2024-Jul The record describes an oncology randomized trial (RADICALS-RT) with a primary time-to-event endpoint (freedom from distant metastasis, OS) and reports original results. However, the trial compares adjuvant radiotherapy to an observation/salvage radiotherapy policy; the intervention is radiotherapy, not a drug-containing regimen. Therefore, it does not meet the required criterion of having a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes. PMID 38553649 · Breast Cancer Res Treat · 2024-Jul Study is an oncology RCT in humans with an original result, but it fails three key eligibility criteria: the intervention is dietary (not drug-containing), the phase is not definitively established as Phase III/IIIb or II/III, and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015). PMID 38546797 · Ann Surg Oncol · 2024-Jul The study meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided title, abstract, or metadata. The criteria require the phase to be explicitly established. The deterministic review signal indicates phase evidence is unclear. Therefore, is_eligible is set to false due to insufficient explicit phase information.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation. PMID 38521641 · J Geriatr Oncol · 2024-Jul This is a clinical trial protocol for a pilot study (TOPCOP3). While it involves metastatic prostate cancer patients on androgen receptor axis-targeted therapy (ARATs), the study interventions are geriatric assessment and management (GA+M) and remote symptom monitoring (RSM), which are supportive care interventions, not a drug-containing intervention as defined for eligibility. Furthermore, the co-primary outcomes are grade 3-5 toxicity and quality of life (QOL), which are not time-to-event efficacy endpoints (like OS, PFS, etc.). The publication is explicitly a 'protocol' and does not report results. Therefore, it is excluded based on: 1) non-drug-only intervention, 2) primary outcome not time-to-event, and 3) being a protocol without results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessment of local complications with preoperative versus postoperative radiotherapy in patients with soft tissue sarcoma in extremities: A randomized comparative clinical trial. PMID 38464549 · J Orthop · 2024-Jul The study is a randomized Phase II clinical trial comparing preoperative vs. postoperative radiotherapy (non-drug intervention) for soft tissue sarcoma. It does not meet the criteria for a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets. PMID 38429253 · Int J Stroke · 2024-Jul The record describes an open-label, randomized, pilot trial in cancer patients, comparing edoxaban to enoxaparin. While it is oncology, human, randomized, and reports original results with a drug intervention, it fails key eligibility criteria: (1) It is explicitly a Phase I/II-level 'pilot trial', not a definitive Phase III or II/III trial. (2) The primary endpoint is a biomarker change (serum D-dimer level), not a time-to-event efficacy endpoint. (3) Although stroke recurrence is mentioned as a secondary endpoint, it is not analyzed or presented as a primary or key secondary time-to-event endpoint with Kaplan-Meier curves or hazard ratios in this report. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
99mTcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial. PMID 38346924 · BJU Int · 2024-Jul The record describes a trial protocol for a randomized oncology study with a time-to-event primary endpoint. However, it is not a formal result report (e.g., primary, interim, final, updated, long-term). Furthermore, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, and the drug intervention criterion is ambiguous as the primary comparison involves a surgical procedure with ADT (a drug), but the study's core novelty is the surgical component. Therefore, eligibility cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. PMID 38244697 · Transplant Cell Ther · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer. PMID 38196077 · Thromb Haemost · 2024-Jul The study is an oncology, human, randomized trial with a drug intervention (apixaban vs. dalteparin) and reports original results. However, the primary efficacy endpoint is the incidence of recurrent VTE, which is a binary, time-specific event (at 7, 30, 90 days), not a time-to-event outcome like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier analysis or hazard ratio for such an endpoint is mentioned. The report type is secondary (early time course analysis of the main trial). Phase is not explicitly established in the provided metadata (CARAVAGGIO trial phase is not stated). Therefore, it does not meet the criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of MC-003 solution for endoscopic mucosal or submucosal resection: a prospective, multicenter, randomized, triple-blinded, parallel-group, phase III study. PMID 38184114 · Gastrointest Endosc · 2024-Jul The study is a Phase III randomized trial in human oncology (gastric adenoma/early cancer) but does not meet the key eligibility criteria: it lacks a time-to-event primary/secondary efficacy endpoint (like OS, PFS) and its intervention is a procedural injectable solution, not a drug-containing systemic therapy for cancer.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of PD-1/PD-L1 Inhibitor and Chemotherapy in Treatment of Advanced Small Cell Lung Cancer. PMID 37971453 · Altern Ther Health Med · 2024-Jul The study is an oncology randomized controlled trial with drug intervention and original results, but it fails two key criteria: (1) the phase is not specified as Phase III/IIIb or Phase II/III (metadata and abstract do not confirm a definitive phase), and (2) a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) with time-to-event data (Kaplan-Meier, HR) is not explicitly reported; 'median survival time' is mentioned but without specification of the endpoint type or supporting time-to-event analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. PMID 37923633 · Eur Urol Focus · 2024-Jul The record describes a randomized feasibility study (pilot/preliminary) with 30 patients, not a definitive Phase III or Phase II/III trial. The primary outcome is patient recruitment rate, which is a feasibility metric. While time-to-event secondary endpoints (recurrence-free and progression-free survival) are reported, the study is not a Phase III/IIIb or Phase II/III trial as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Subxiphoid versus lateral intercostal thoracoscopic thymectomy for suspected thymoma: Results of a randomized controlled trial. PMID 37890660 · J Thorac Cardiovasc Surg · 2024-Jul The study is a randomized controlled trial for thymoma (oncology) with original results, but it does not meet key eligibility criteria: (1) Phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the trial is primarily a surgical (thymectomy) intervention study, not a drug trial; (2) The primary endpoints are pain score, length of stay, and opioid consumption, not time-to-event efficacy outcomes (OS, PFS, DFS, etc.); (3) The intervention is surgical approach comparison, not a drug-containing regimen. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. PMID 38297352 · Breast Cancer Res · 2024-Jan-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis. PMID 38294563 · Support Care Cancer · 2024-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -